LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Thera… Read more
Market Cap & Net Worth: LENZ Therapeutics Inc (LENZ)
LENZ Therapeutics Inc (NASDAQ:LENZ) has a market capitalization of $391.12 Million ($391.12 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13811 globally and #5656 in its home market, demonstrating a 1.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LENZ Therapeutics Inc's stock price $12.50 by its total outstanding shares 31289969 (31.29 Million).
LENZ Therapeutics Inc Market Cap History: 2021 to 2026
LENZ Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $262.96 Million to $391.12 Million (-0.01% CAGR).
Index Memberships
LENZ Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #373 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1330 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.02% | #201 of 263 |
Weight: LENZ Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
LENZ Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LENZ Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.68x
LENZ Therapeutics Inc's market cap is 4.68 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $70.24 Million | $15.00 Million | -$10.81 Million | 4.68x | N/A |
Competitor Companies of LENZ by Market Capitalization
Companies near LENZ Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to LENZ Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
LENZ Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, LENZ Therapeutics Inc's market cap moved from $262.96 Million to $ 391.12 Million, with a yearly change of -0.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $391.12 Million | -21.88% |
| 2025 | $500.64 Million | -45.83% |
| 2024 | $924.12 Million | +1567.27% |
| 2023 | $55.43 Million | -21.09% |
| 2022 | $70.24 Million | -73.29% |
| 2021 | $262.96 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of LENZ Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $391.12 Million USD |
| MoneyControl | $391.12 Million USD |
| MarketWatch | $391.12 Million USD |
| marketcap.company | $391.12 Million USD |
| Reuters | $391.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.